# GLP-1 Drugs Linked to Lower Death Risk in Older Adults With Fatty Liver

*GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study.*

- **Evidence Level**: Moderate
- **Why this grade**: Large retrospective cohort with propensity matching of about 88,000 older adults over up to 10 years, though treatment was not randomly assigned.
- **Facts**: Duration: 10 years
- **Publication Types**: Journal Article
- **Journal**: Age and ageing
- **Sample Size**: 87,860 adults aged 65+ with fatty liver disease
- **Authors**: Koutouratsas T, Kalligeros M, Michael M, Das S, Mylonakis SC, Mylonakis E
- **Graded and published**: 2026-09-04
- **Last edited**: 2026-09-23
- **Topics**: GLP-1, liver health, healthy aging
- **DOI**: https://doi.org/10.1093/ageing/afag281
- **Original Source**: https://pubmed.ncbi.nlm.nih.gov/42765724/

## Summary

Older adults with fatty liver disease who started a GLP-1 drug had about half the death rate of those who did not. Researchers matched around 44,000 people over 65 on each side using US medical records, tracking them up to 10 years. Liver complications and hospital stays were also lower, though heart events were not. This was not a randomized trial, so other differences between the groups could explain part of the gap, and some side effects like eye problems were more common.

## Practical Takeaway

This study suggests GLP-1 drugs may be worth discussing with a doctor for fatty liver disease.

---

_Canonical: https://longevity-germany.com/en/research/glp-1-drugs-linked-to-lower-death-risk-in-older-adults-with-fatty-liver · Part of Longevity Cities · Updated 2026-09-23_